Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy F Sweis

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Methods in Enzymology|March 4, 2020
Methods to assess anticancer immune responses in orthotopic bladder carcinomasRandy F Sweis
Frontiers in Immunology|November 23, 2020
<i>FGFR3</i> Alterations in the Era of Immunotherapy for Urothelial Bladder CancerAlec Kacew, Randy F Sweis
Advances in Experimental Medicine and Biology|June 29, 2021
The Tumor Microenvironment of Bladder CancerKen Hatogai, Randy F Sweis
Cancer|June 29, 2025
The current and future role of systemic therapy in non-muscle-invasive bladder cancerAlon Lazarovich, Randy F Sweis
Urologic Oncology|November 13, 2016
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkersRandy F Sweis, Matthew D Galsky
Pharmacological Research|March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitorsRandy F Sweis, Jason J Luke
Current Oncology Reports|January 27, 2023
The Development of STING Agonists and Emerging Results as a Cancer ImmunotherapyJacobi B Hines, Alec J Kacew, Randy F Sweis
Journal of the American Chemical Society|June 17, 2004
Silver-catalyzed [2 + 2] cycloadditions of siloxy alkynesRandy F Sweis, Michael P Schramm, Sergey A Kozmin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical TrialsRandy F Sweis, Michael W Drazer, Mark J Ratain
Bladder Cancer (Amsterdam, Netherlands)|November 16, 2020
The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune ResponsivenessCiro Andolfi, Jeffrey C Bloodworth, Apostolos Papachristos, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Methods in Enzymology|March 4, 2020
Methods to assess anticancer immune responses in orthotopic bladder carcinomasRandy F Sweis
Frontiers in Immunology|November 23, 2020
<i>FGFR3</i> Alterations in the Era of Immunotherapy for Urothelial Bladder CancerAlec Kacew, Randy F Sweis
Advances in Experimental Medicine and Biology|June 29, 2021
The Tumor Microenvironment of Bladder CancerKen Hatogai, Randy F Sweis
Cancer|June 29, 2025
The current and future role of systemic therapy in non-muscle-invasive bladder cancerAlon Lazarovich, Randy F Sweis
Urologic Oncology|November 13, 2016
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkersRandy F Sweis, Matthew D Galsky
Pharmacological Research|March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitorsRandy F Sweis, Jason J Luke
Current Oncology Reports|January 27, 2023
The Development of STING Agonists and Emerging Results as a Cancer ImmunotherapyJacobi B Hines, Alec J Kacew, Randy F Sweis
Journal of the American Chemical Society|June 17, 2004
Silver-catalyzed [2 + 2] cycloadditions of siloxy alkynesRandy F Sweis, Michael P Schramm, Sergey A Kozmin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical TrialsRandy F Sweis, Michael W Drazer, Mark J Ratain
Bladder Cancer (Amsterdam, Netherlands)|November 16, 2020
The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune ResponsivenessCiro Andolfi, Jeffrey C Bloodworth, Apostolos Papachristos, et al.
Pageof 6